百奥泰

Bio-Thera Solutions, Ltd., headquartered in Guangzhou, China, operates as an innovative global biopharmaceutical enterprise. The company specializes in the development of cutting-edge therapeutic drugs and biosimilars aimed at treating a broad spectrum of serious health conditions including cancers, autoimmune disorders, cardiovascular diseases, ocular illnesses, and other life-threatening ailments. As a pioneering force in next-generation antibody research, Bio-Thera has propelled several potential medicines through advanced clinical trials. Three of these have been successfully launched in the market, namely QLETLI® in China, and TOFIDENCE™/BAT1806 and Avzivi®/Pobevcy® in both China and the United States. With over 20 investigational products currently under various stages of clinical investigation, the company's focus remains on post-PD-1 era immunotherapies and targeted drug conjugates (ADCs) for oncological applications. Prioritizing patient welfare, Bio-Thera continuously innovates to provide patients with high-quality, efficacious, and affordable treatments to address pressing healthcare needs. For further details, please visit the company's website at www.bio-thera.com/en/ or connect with them on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).